Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02640209
Recruitment Status : Terminated (Study is terminated due to administrative reasons.)
First Posted : December 28, 2015
Last Update Posted : May 7, 2020
Sponsor:
Information provided by (Responsible Party):
University of Pennsylvania